Ascelia Pharma AB Sustainability Reports
Ascelia Pharma AB is a biotech company focused on the development and commercialization of novel drugs and orphan oncology treatments. Its pipeline includes Orviglance, a diagnostic contrast agent for liver MRI scans, and Oncoral, an oral chemotherapy tablet for gastric cancer.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 5493002YR9VCJJPWYN08
FIGI: BBG00KXPN9T7
8 reports from 2018 to 2025
